Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and …

refractory acute myeloid leukemia (aml)
cancer
decitabine
cytarabine
  • 2 views
  • 04 Oct, 2022
  • 55 locations
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

This is a non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with Relapsed or Refractory AML.

refractory acute myeloid leukemia (aml)
  • 7 views
  • 21 Mar, 2022
  • 1 location
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)

This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of anti-CLL1 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CLL1 positive relapsed or refractory acute myeloid leukemia.

refractory acute myeloid leukemia (aml)
  • 5 views
  • 20 May, 2021
  • 1 location
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD mutation.

refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia
potassium
calcium
serum bilirubin level
  • 0 views
  • 04 Oct, 2022
  • 1 location
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

cancer
acute leukemia
acute promyelocytic leukemia
idarubicin
granulocyte colony stimulating factor
  • 1 views
  • 05 Mar, 2022
  • 1 location
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

secondary acute myeloid leukemia
refractory acute myeloid leukemia (aml)
hydroxyurea
cell transplantation
serum bilirubin level
  • 0 views
  • 12 Oct, 2022
  • 8 locations
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML).

refractory acute myeloid leukemia (aml)
tyrosine
ejection fraction
  • 0 views
  • 07 Oct, 2022
  • 6 locations
First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib (KO-539), a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid

refractory acute myeloid leukemia (aml)
renal function
hydroxyurea
blast cells
serum bilirubin level
  • 2 views
  • 09 May, 2022
  • 23 locations
A Phase 1, Open-label, Dose-escalation Trial of CD33xCD3 Bispecific Antibody in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and

  • 0 views
  • 22 Oct, 2022
  • 12 locations
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

refractory acute myeloid leukemia (aml)
chronic myelomonocytic leukemia
hydroxyurea
tyrosine
flt3 internal tandem duplication
  • 6 views
  • 03 Feb, 2022
  • 4 locations